标题
Covalent-Allosteric Kinase Inhibitors
作者
关键词
-
出版物
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 54, Issue 35, Pages 10313-10316
出版商
Wiley
发表日期
2015-06-25
DOI
10.1002/anie.201502142
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of Inter-Domain Stabilizers—A Novel Assay System for Allosteric Akt Inhibitors
- (2014) Zhizhou Fang et al. ACS Chemical Biology
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
- (2014) M. Y. Konopleva et al. CLINICAL CANCER RESEARCH
- Critical cysteines in Akt1 regulate its activity and proteasomal degradation: implications for neurodegenerative diseases
- (2014) Faraz Ahmad et al. FREE RADICAL BIOLOGY AND MEDICINE
- Advances in kinase targeting: current clinical use and clinical trials
- (2014) Mathias Rask-Andersen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation
- (2014) Thuy Nguyen et al. ACS Medicinal Chemistry Letters
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- A kinase-independent function of AKT promotes cancer cell survival
- (2014) Igor Vivanco et al. eLife
- Kinase Drug Discovery – What’s Next in the Field?
- (2013) Philip Cohen et al. ACS Chemical Biology
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree
- (2013) Matthieu Chartier et al. PeerJ
- Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features
- (2012) Zhizhou Fang et al. ACS Chemical Biology
- Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors
- (2012) Mark A. Ashwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT
- (2012) Jason G. Kettle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
- (2012) Tjeerd Barf et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
- (2012) Tsukasa Yoshida et al. MEDICAL ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Akt signalling in health and disease
- (2011) Ingeborg Hers et al. CELLULAR SIGNALLING
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation
- (2010) Justine Rudner et al. Radiation Oncology
- Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model
- (2008) Mark T. Bilodeau et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started